Cns Total Assets vs Total Current Assets Analysis

CNSP Stock  USD 0.12  0.01  7.69%   
Cns Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cns Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cns Pharmaceuticals is a good investment. Please check the relationship between Cns Pharmaceuticals Total Assets and its Total Current Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.

Total Assets vs Total Current Assets

Total Assets vs Total Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cns Pharmaceuticals Total Assets account and Total Current Assets. At this time, the significance of the direction appears to have totally related.
The correlation between Cns Pharmaceuticals' Total Assets and Total Current Assets is 1.0. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Cns Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cns Pharmaceuticals' Total Assets and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Cns Pharmaceuticals are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Total Assets i.e., Cns Pharmaceuticals' Total Assets and Total Current Assets go up and down completely randomly.

Correlation Coefficient

1.0
Relationship DirectionPositive 
Relationship StrengthVery Strong

Total Assets

Total assets refers to the total amount of Cns Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cns Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.
Most indicators from Cns Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.As of 11/28/2024, Issuance Of Capital Stock is likely to grow to about 9.7 M, while Selling General Administrative is likely to drop slightly above 3.6 M.
 2021 2022 2023 2024 (projected)
Total Operating Expenses14.0M15.3M18.9M9.9M
Research Development9.3M9.3M14.1M14.8M

Cns Pharmaceuticals fundamental ratios Correlations

0.81-0.050.320.910.86-0.98-0.390.230.990.990.740.150.770.670.740.640.320.920.811.00.90.810.43-0.80.42
0.810.350.590.60.87-0.76-0.660.530.770.770.82-0.360.550.860.690.770.590.611.00.810.581.00.41-0.920.38
-0.050.350.88-0.430.380.12-0.850.92-0.11-0.110.51-0.6-0.140.680.240.630.88-0.420.35-0.05-0.450.35-0.21-0.46-0.24
0.320.590.88-0.10.58-0.21-0.980.990.230.230.76-0.310.340.870.660.871.0-0.080.590.31-0.130.59-0.19-0.69-0.09
0.910.6-0.43-0.10.65-0.940.02-0.180.940.940.440.290.650.330.490.29-0.11.00.60.911.00.60.54-0.540.48
0.860.870.380.580.65-0.83-0.660.540.840.840.88-0.250.450.870.610.80.580.660.870.860.640.870.44-0.930.34
-0.98-0.760.12-0.21-0.94-0.830.28-0.13-1.0-1.0-0.65-0.13-0.7-0.58-0.65-0.54-0.21-0.94-0.76-0.99-0.94-0.76-0.410.73-0.32
-0.39-0.66-0.85-0.980.02-0.660.28-0.98-0.29-0.29-0.830.32-0.37-0.92-0.69-0.92-0.980.0-0.66-0.370.05-0.660.070.79-0.06
0.230.530.920.99-0.180.54-0.13-0.980.140.140.72-0.340.240.850.590.840.99-0.170.530.22-0.210.53-0.18-0.68-0.07
0.990.77-0.110.230.940.84-1.0-0.290.141.00.660.130.70.590.660.550.230.940.770.990.930.770.41-0.740.33
0.990.77-0.110.230.940.84-1.0-0.290.141.00.660.130.70.590.660.550.230.940.770.990.930.770.41-0.740.33
0.740.820.510.760.440.88-0.65-0.830.720.660.66-0.180.570.930.740.970.760.450.820.720.410.820.26-0.910.36
0.15-0.36-0.6-0.310.29-0.25-0.130.32-0.340.130.13-0.180.54-0.310.3-0.17-0.310.28-0.360.140.28-0.36-0.160.240.12
0.770.55-0.140.340.650.45-0.7-0.370.240.70.70.570.540.480.910.580.340.660.550.760.630.550.02-0.540.29
0.670.860.680.870.330.87-0.58-0.920.850.590.590.93-0.310.480.740.940.870.340.860.660.30.860.25-0.940.3
0.740.690.240.660.490.61-0.65-0.690.590.660.660.740.30.910.740.80.660.510.690.730.460.69-0.02-0.750.25
0.640.770.630.870.290.8-0.54-0.920.840.550.550.97-0.170.580.940.80.870.30.770.630.260.770.05-0.890.22
0.320.590.881.0-0.10.58-0.21-0.980.990.230.230.76-0.310.340.870.660.87-0.080.590.31-0.130.59-0.19-0.69-0.09
0.920.61-0.42-0.081.00.66-0.940.0-0.170.940.940.450.280.660.340.510.3-0.080.610.921.00.610.54-0.550.48
0.811.00.350.590.60.87-0.76-0.660.530.770.770.82-0.360.550.860.690.770.590.610.810.581.00.41-0.920.38
1.00.81-0.050.310.910.86-0.99-0.370.220.990.990.720.140.760.660.730.630.310.920.810.910.810.41-0.790.38
0.90.58-0.45-0.131.00.64-0.940.05-0.210.930.930.410.280.630.30.460.26-0.131.00.580.910.580.52-0.520.43
0.811.00.350.590.60.87-0.76-0.660.530.770.770.82-0.360.550.860.690.770.590.611.00.810.580.41-0.920.38
0.430.41-0.21-0.190.540.44-0.410.07-0.180.410.410.26-0.160.020.25-0.020.05-0.190.540.410.410.520.41-0.350.84
-0.8-0.92-0.46-0.69-0.54-0.930.730.79-0.68-0.74-0.74-0.910.24-0.54-0.94-0.75-0.89-0.69-0.55-0.92-0.79-0.52-0.92-0.35-0.4
0.420.38-0.24-0.090.480.34-0.32-0.06-0.070.330.330.360.120.290.30.250.22-0.090.480.380.380.430.380.84-0.4
Click cells to compare fundamentals

Cns Pharmaceuticals Account Relationship Matchups

Cns Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets7.9M15.9M8.8M13.1M1.7M1.6M
Other Current Liab21.5K519.8K224.9K828.4K5.8M6.1M
Total Current Liabilities311.0K1.9M2.1M4.9M6.1M6.4M
Total Stockholder Equity7.6M13.9M6.6M8.1M(4.4M)(4.2M)
Net Tangible Assets(549.3K)7.6M13.6M6.6M7.6M6.0M
Net Debt(7.2M)(13.6M)(4.6M)(9.6M)(247.9K)(260.3K)
Retained Earnings(11.5M)(20.9M)(35.0M)(50.7M)(69.6M)(66.1M)
Accounts Payable289.5K946.3K2.0M3.7M5.8M6.1M
Cash7.2M14.0M5.0M10.1M548.7K521.3K
Non Current Assets Total18.2K357.6K1.3M488.5K109.7K104.2K
Cash And Short Term Investments7.2M14.0M5.0M10.1M548.7K521.3K
Common Stock Shares Outstanding548.3K11.1M17.6M27.2M75.3K71.6K
Liabilities And Stockholders Equity7.9M15.9M8.8M13.1M1.7M1.6M
Non Current Liabilities Total445.8K289.5K1.4M1.9M4.1M0.0
Other Current Assets652.6K1.5M2.5M5.0M1.0M1.7M
Other Stockholder Equity19.1M34.9M41.6M58.8M65.1M35.6M
Total Liab311.0K1.9M2.1M4.9M6.1M6.4M
Net Invested Capital7.6M14.4M7.0M8.5M(4.1M)(3.9M)
Total Current Assets7.9M15.5M7.5M12.6M1.6M1.5M
Net Working Capital7.6M13.6M5.3M7.6M(4.5M)(4.3M)
Common Stock16.5K23.9K27.9K1.6K6.2K11.3K
Capital Stock16.5K23.9K27.9K1.6K6.2K11.8K

Pair Trading with Cns Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cns Stock

  0.67VALN Valneva SE ADRPairCorr
  0.76FDMT 4D Molecular TherapeuticsPairCorr
  0.64JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.62LLY Eli Lilly Sell-off TrendPairCorr

Moving against Cns Stock

  0.7BMY Bristol Myers Squibb Aggressive PushPairCorr
  0.65GILD Gilead SciencesPairCorr
  0.54LPCN LipocinePairCorr
  0.54NAMS NewAmsterdam PharmaPairCorr
  0.45OPT OptheaPairCorr
The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.
The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Cns Stock Analysis

When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.